Generate Biomedicines, Inc. (GENB) stock
GENBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$9.84−0.65 (-6.20%)
Close on Nov 17, 2026Market cap $1.26BP/E –Yield –
Generate Biomedicines profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -2077.2% | −1559.6 |
| Q2 FY2026 | Jun 30, 2026 | -1065.2% | −592.4 |
| Q1 FY2026 | Mar 31, 2026 | -850.6% | – |
| Q3 FY2025 | Sep 30, 2025 | -556.5% | – |
| Q2 FY2025 | Jun 30, 2025 | -517.6% | – |
| Q1 FY2025 | Mar 31, 2025 | -472.7% | – |
See a number that looks wrong?